CoChat

Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives

Martinotti, Giovanni, Orsolini, Laura, Fornaro, Michele, Vecchiotti, Roberta, De Berardis, Domenico, Iasevoli, Felice, Torrens, Marta, Di Giannantonio, Massimo · 2016 · Expert Opinion on Investigational Drugs
Cited by 42

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Among other approaches, the modulation of the dopaminergic pathway has been advocated in the therapeutic management of Alcohol Use Disorders (AUD). A potential avenue toward the modulation of the dopaminergic pathway across varying substance disorders seems to be provided by aripiprazole, a second-generation antipsychotic characterized by a peculiar pharmacodynamics signature. AREAS COVERED: In this review, the authors provided a qualitative synthesis and a critical perspective on the efficacy of aripiprazole in relapse prevention and craving in AUD. A systematic search was carried out through MEDLINE/Embase/PsycINFO/Cochrane Library from inception until September 2015, combining free terms and MESH headings for the topics of AUD and aripiprazole as following: (((Alcohol use Disorder) OR (Alcohol use)) AND aripiprazole). EXPERT OPINION: Based both on a qualitative synthesis and a critical interpretation of the evidence, the authors submit that aripiprazole would promote alcohol abstinence and reduce the alcohol seeking behaviour possibly via dopaminergic and serotoninergic modulations at the fronto-subcortical circuits underpinning alcohol reward and craving, impulsive behaviour as well as reduce alcohol-related anxiety/low mood and anhedonia. However, due to the lack of published studies, a conclusive statement about any direct effect of aripiprazole in the prevention of craving and/or alcohol consumption is not possible.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/13543784.2016.1175431

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 42

Metadata

Authors
Martinotti, G., Orsolini, L., Fornaro, M., Vecchiotti, R., De Berardis, D., Iasevoli, F., Torrens, M., & Di Giannantonio, M.
Venue
Expert Opinion on Investigational Drugs
Published
2016-04-21
Volume
25
Issue
6
Pages
719-728
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W2339758256
Cited by
42
References
9
FWCI
4.09
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. https://app.cochat.ai/papers/10.1080/13543784.2016.1175431
The paper
Martinotti, G., Orsolini, L., Fornaro, M., Vecchiotti, R., De Berardis, D., Iasevoli, F., Torrens, M., & Di Giannantonio, M. (2016). Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2016.1175431

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.